Tag: Bavencio

FDA granted accelerated approval to Avelumab (BAVENCIO) for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma (MCC). MCC is a Neuroendocrine Carcinoma of the skin. Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody, i.e. Immunotherapy

Clinical Trials and Research, TreatmentAdvanced neuroendocrine cancer, Anti-angiogenic therapy, Atezolizumab (Tecentriq), Avelumab (Bavencio), Avistan, Bavencio, Bevacizumab, Cisplatin, Colorectal cancer, DLL3, EGFR, Epidermal growth factor receptor (EGFR), Fluoropyrimidine, Head and Neck Cancer, Hodgkin lymphoma, Immunotherapy, Ipilimumab (Yervoy), Keytruda, Lanreotide, Melanoma, Microsatellite instability-high (MSI-H), Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Nivolumab (Opdivo), Non-small cell lung cancer (NSCLC), Paraganglioma, PD-1/PD-L1 Inhibitors, PDR001, Pembrolizumab (Keytruda), Pemetrexed disodium, Pheochromocytoma, Solid tumour, Squamous cell carcinoma, Tecentriq (Atezolizumab), Tumour mutational burden (TMB), Typical lung NET, Yervoy

Immunotherapy and Neuroendocrine Neoplasms

By Ronny Allan Sep 25, 2025 8 Comments

Our website use cookies to improve and personalize your experience and to display advertisements(if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click on the button to check our Privacy Policy.

Ok, I Agree